Cryoport(CYRX) Prnewswire·2025-01-21 13:30Core Insights - Cryoport, Inc. has introduced the Cryoport Express® Cryogenic HV3 Shipping System, enhancing patient access to critical therapies and showcasing it at Phacilitate's Advanced Therapies Week in Dallas [1][5] Product Features - The HV3 shipping system offers unparalleled protection for biologics, eliminating the need for palletization and allowing transport on narrow-bodied aircraft, thus increasing shipping lanes and improving patient access [2][3] - It provides enhanced payload protection, resilience during transport, and improved storage efficiency through stackable design, while maintaining temperature stability at -150°C or lower [3][4] - The system is designed for mobility with robust wheels and a front-facing handle, facilitating efficient handling at various sites, including point-of-care and manufacturing locations [4][6] Company Commitment - The CEO of Cryoport emphasized the company's commitment to addressing industry challenges and improving patient outcomes through innovative solutions like the HV3 [5] - The Chief Product Development Officer highlighted the user-centric design of the HV3, aimed at overcoming logistical challenges in transporting advanced therapies globally [6] Company Overview - Cryoport, Inc. is a global leader in supply chain solutions for life sciences, focusing on cell and gene therapies, and offers a wide range of services to ensure compliance and efficiency in the supply chain [7][8]